(Q41319701)

English

Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials

scientific article published on 2 October 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

29 September 2017

Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials (English)

1 reference

Europe PubMed Central

PMC publication ID

29 September 2017

author name string

A Som

1

1 reference

Europe PubMed Central

PMC publication ID

29 September 2017

S-M Tu

2

1 reference

Europe PubMed Central

PMC publication ID

29 September 2017

J Liu

3

1 reference

Europe PubMed Central

PMC publication ID

29 September 2017

X Wang

4

1 reference

Europe PubMed Central

PMC publication ID

29 September 2017

W Qiao

5

1 reference

Europe PubMed Central

PMC publication ID

29 September 2017

C Logothetis

6

1 reference

Europe PubMed Central

PMC publication ID

29 September 2017

P G Corn

7

1 reference

Europe PubMed Central

PMC publication ID

29 September 2017

language of work or name

0 references

publication date

2 October 2012

1 reference

Europe PubMed Central

PMC publication ID

29 September 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

29 September 2017

107

1 reference

Europe PubMed Central

PMC publication ID

29 September 2017

9

1 reference

Europe PubMed Central

PMC publication ID

29 September 2017

1547-1553

1 reference

Europe PubMed Central

PMC publication ID

29 September 2017

https://scigraph.springernature.com/pub.10.1038/bjc.2012.436

0 references

Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

1 October 2017

Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

1 October 2017

Novel therapies for metastatic castrate-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

1 October 2017

Emerging therapies to prevent skeletal morbidity in men with prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

1 October 2017

Imaging metastatic bone disease from carcinoma of the prostate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

1 October 2017

Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

1 October 2017

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

1 October 2017

Bone imaging in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

1 October 2017

Understanding the biology of bone metastases: key to the effective treatment of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

1 October 2017

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

1 October 2017

Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

1 October 2017

A new computer-based decision-support system for the interpretation of bone scans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

1 October 2017

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

1 October 2017

Osteoblasts in prostate cancer metastasis to bone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

1 October 2017

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

1 October 2017

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

1 October 2017

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

14 June 2018

Stromal targeted therapy in bone metastatic prostate cancer: promise delivered.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

14 June 2018

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

14 June 2018

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

19 August 2018

Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

19 August 2018

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

19 August 2018

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

19 August 2018

A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3493771

19 August 2018

The flare phenomenon on radionuclide bone scan in metastatic prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23033003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessing response in bone metastases in prostate cancer with diffusion weighted MRI

1 reference

https://pubmed.ncbi.nlm.nih.gov/23033003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23033003

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.2012.436

1 reference

Europe PubMed Central

PMC publication ID

29 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

29 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

29 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41319701&oldid=2095882667"